Volume 2 Issue 4
Physeal Distraction During Surgical Treatment of Osteosarcoma of the Femury
Yao Weitao*, Cai Qiqing, Wang Jiaqian, Gao Songtao
Osteosarcoma is a primary, malignant, bone tumor that occurs in young, growing patients. The most frequently affected parts are the distal femur and proximal tibia. With improvements in adjuvant chemotherapy, the survival rates of patients with osteosarcomas have increased from 20% to 60%–80%. In recent years, amputation can be avoided in 80%–90% of patients owing to the availability of various limb-saving procedures, such as tumor prosthesis implantation and biologic reconstruction, which can adapt to the long-term functional demands of these patients.
Study of Methylation Status in TET2 Mutations in Iranian Breast Cancer Patient
Sohila Asoudeh Moghanloo, Mohammad Navaderi*
TET2 enzymatic ally converts 5-methyl-cytosine to 5-hydroxymethyl-cytosine, possibly leading to loss of DNA methylation. Genetic mutations of TET2 gene were associated with leukemia, whereas TET1 down regulation has been shown to promote malignancy in breast cancer. To expand on this concept, we studied methylation status in TET2 gene in Breast Cancer (BC) samples. TET2 Messene or nonsense mutations were detected in 53% (16/30) of patients.
Updates in Prostate Cancer: A Review on Management of Metastatic Disease
Gauri Gogna MBBChBAO*, Pretoria Bilinski MBBS FRACP MPallC FAChPM MHA
Prostate cancer is the most common non-cutaneous malignancy to effect men in Australia, and is the 5th leading cause of death. The management can be difficult in patients with a denovo presentation with metastatic castrate sensitive disease, or who progress to metastatic castration resistant prostate cancer. Since 2004 there have been multiple new agents for the treatment of this disease, both systemically and specifically for bony metastasis. This review aims to give doctors an overview of these medications, their side effects and their evidence base so they may provide good overall patient care.